MannKind (MNKD) said Monday the six-month results of its phase 3 INHALE-1 study showed inhaled insulin Afrezza in children and adolescents aged four to 17 established the non-inferiority of Afrezza to multiple daily injections, which was the primary endpoint of the study.
The study compared Afrezza with multiple daily injections of rapid-acting insulin analogs, alongside basal insulin, over 26 weeks. Results from the modified intent-to-treat analysis confirmed that Afrezza met the non-inferiority threshold in HbA1c change compared with multiple daily injections.
No significant differences in lung function or safety, including hypoglycemia, were observed between the groups over the 26-week-period.
MannKind said it plans to meet with the FDA to discuss filing a supplemental new drug application in H1 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。